Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/798
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor | Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP | - |
dc.contributor.author | CONDI, F. L. F. | - |
dc.contributor.author | SOARES JR., J. M. | - |
dc.contributor.author | TEODORO, W. R. | - |
dc.contributor.author | VELOSO, A. P. | - |
dc.contributor.author | PARRA, E. R. | - |
dc.contributor.author | SIMOES, M. de Jesus | - |
dc.contributor.author | BARACAT, E. C. | - |
dc.date.accessioned | 2013-07-30T15:08:56Z | - |
dc.date.available | 2013-07-30T15:08:56Z | - |
dc.date.issued | 2012 | - |
dc.identifier.citation | CLIMACTERIC, v.15, n.5, p.441-448, 2012 | - |
dc.identifier.issn | 1369-7137 | - |
dc.identifier.uri | https://observatorio.fm.usp.br/handle/OPI/798 | - |
dc.description.abstract | Objective To evaluate the action of conjugated equine estrogen, raloxifene and isolated or combined genistein-rich soy extracts on collagen fibers in the bones of oophorectomized rats. Materials and methods Seventy female rats received testosterone propionate (0.1 mu g/g) on the 9th day after birth. At 6 months of age, the rats were administered the vehicle (propylene glycol, 0.5 ml/day), and ten of the rats were randomly chosen to comprise the non-oophorectomized control group (GI). The other 60 rats were ovariectomized and randomized into six groups of ten as follows: GII, vehicle; GIII, conjugated equine estrogen (CEE), 50 mu g/kg/day; GIV, raloxifene (RAL), 0.75 mg/kg/day; GV, genistein-rich soy extract (GSE), 300 mg/kg/day; GVI, CEE + GSE, 50 mu g/kg/day + 300 mg/kg/day; and GVII, CEE + RAL, 50 mu g/kg/day + 0.75 mg/kg/day. Three months after surgery, the drugs were administered for 60 consecutive days. All rats were euthanized, and their left tibiae were removed for histological routine. The histological sections were stained with hematoxylin-eosin, and picrosirius for evaluating bone microarchitecture. Types I and II collagen fibers were analyzed by immunofluorescence. Data analysis was carried out with ANOVA and Tukey's test. Results Collagen reduction was significant in the GIII animals when compared to the other groups (p < 0.05). There was no significant difference in the thickness of collagen fibers among the groups. There was a greater quantity of type III collagen in GVI than in the other groups. Conclusion Our data indicate that conjugated equine estrogen improves bone quality because it increases the quantity of type I collagen while reducing the quantity of thin collagen fibers. In addition, the combination of CEE and raloxifene or genistein-rich soy extract is not as efficient as CEE itself to improve bone quality. | - |
dc.description.sponsorship | FAPESP, Sao Paulo, Brazil | - |
dc.description.sponsorship | CAPES, Brasilia, Brazil | - |
dc.language.iso | eng | - |
dc.publisher | INFORMA HEALTHCARE | - |
dc.relation.ispartof | Climacteric | - |
dc.rights | restrictedAccess | - |
dc.subject | CONJUGATED EQUINE ESTROGEN | - |
dc.subject | RALOXIFENE | - |
dc.subject | GENISTEIN-RICH SOY EXTRACT | - |
dc.subject | BONE | - |
dc.subject | FEMALE RATS | - |
dc.subject.other | ovariectomized rats | - |
dc.subject.other | genistein | - |
dc.subject.other | receptor | - |
dc.subject.other | tissue | - |
dc.subject.other | phytoestrogens | - |
dc.subject.other | fibers | - |
dc.subject.other | model | - |
dc.subject.other | beta | - |
dc.title | The effects of conjugated estrogen, raloxifene and soy extract on collagen in rat bones | - |
dc.type | article | - |
dc.rights.holder | Copyright INFORMA HEALTHCARE | - |
dc.identifier.doi | 10.3109/13697137.2011.624213 | - |
dc.identifier.pmid | 22208761 | - |
dc.subject.wos | Obstetrics & Gynecology | - |
dc.type.category | original article | - |
dc.type.version | publishedVersion | - |
hcfmusp.author.external | SIMOES, M. de Jesus:Univ Fed Sao Paulo, Dept Histol & Cellular Biol, Sao Paulo, Brazil | - |
hcfmusp.description.beginpage | 441 | - |
hcfmusp.description.endpage | 448 | - |
hcfmusp.description.issue | 5 | - |
hcfmusp.description.volume | 15 | - |
hcfmusp.origem | WOS | - |
hcfmusp.origem.id | WOS:000308942500006 | - |
hcfmusp.origem.id | 2-s2.0-84866352758 | - |
hcfmusp.publisher.city | LONDON | - |
hcfmusp.publisher.country | ENGLAND | - |
hcfmusp.relation.reference | Albertazzi P, 2002, CLIMACTERIC, V5, P190, DOI 10.1080/713605224 | - |
hcfmusp.relation.reference | Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593 | - |
hcfmusp.relation.reference | Anderson JJB, 1998, P SOC EXP BIOL MED, V217, P345 | - |
hcfmusp.relation.reference | Archer DF, 2010, DRUG AGING, V27, P533, DOI 10.2165/11316000-000000000-00000 | - |
hcfmusp.relation.reference | Baracat EC, 1998, MENOPAUSE, V5, P263, DOI 10.1097/00042192-199805040-00089 | - |
hcfmusp.relation.reference | Bryant HU, 1996, OSTEOPOROS INT S1, V6, P233, DOI 10.1007/BF02500468 | - |
hcfmusp.relation.reference | Cai DJ, 2005, J BONE MINER RES, V20, P828, DOI 10.1359/JBMR.041236 | - |
hcfmusp.relation.reference | Carrin VS, 2006, OSTEOPOROS INT 0421, V17, P319 | - |
hcfmusp.relation.reference | Chiechi KM, 1999, INT J GYNECOL, V67, P39 | - |
hcfmusp.relation.reference | Deroo BJ, 2006, J CLIN INVEST, V116, P561, DOI 10.1172/JCI27987 | - |
hcfmusp.relation.reference | KEENE DR, 1991, J HISTOCHEM CYTOCHEM, V39, P59 | - |
hcfmusp.relation.reference | Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863 | - |
hcfmusp.relation.reference | Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252 | - |
hcfmusp.relation.reference | MESSINA MJ, 1994, NUTR CANCER, V21, P113 | - |
hcfmusp.relation.reference | Moraes AVC, 2006, REV BRAS GINECOL OBS, V28, P101 | - |
hcfmusp.relation.reference | Nachtigall L, 2001, J BR MENOPAUSE SO S1, P8 | - |
hcfmusp.relation.reference | Reinwald S, 2010, J OSTEOPOROSIS | - |
hcfmusp.relation.reference | Rizk DEE, 2008, INT UROGYNECOL J, V19, P547, DOI 10.1007/s00192-007-0462-1 | - |
hcfmusp.relation.reference | Setchell KD, 2001, J NUTR, V131, P1362 | - |
hcfmusp.relation.reference | Shen ZL, 2008, BIOPHYS J, V95, P3956, DOI 10.1529/biophysj.107.124602 | - |
hcfmusp.relation.reference | Sliwinski L, 2009, ACTA BIOCHIM POL, V56, P261 | - |
hcfmusp.relation.reference | Swaminathan R, 2001, CLIN CHIM ACTA, V313, P95, DOI 10.1016/S0009-8981(01)00656-8 | - |
hcfmusp.relation.reference | Tamura N, 2005, FERTIL STERIL, V84, P1277, DOI 10.1016/j.fertnstert.2005.06.017 | - |
hcfmusp.relation.reference | Vasilceac FA, 2011, RHEUMATOL INT, V31, P737, DOI 10.1007/s00296-010-1371-z | - |
hcfmusp.relation.reference | Velosa APP, 2007, REV BRAS REUMATOL, V47, P401, DOI 10.1590/S0482-50042007000600003 | - |
hcfmusp.relation.reference | Viguet-Carrin S, 2006, OSTEOPOROSIS INT, V17, P319, DOI 10.1007/s00198-005-2035-9 | - |
hcfmusp.relation.reference | Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550 | - |
hcfmusp.relation.reference | Yoles I, 2003, MENOPAUSE, V10, P522, DOI 10.1097/01.GME.0000064864.58809.77 | - |
dc.description.index | MEDLINE | - |
hcfmusp.remissive.sponsorship | CAPES | - |
hcfmusp.remissive.sponsorship | FAPESP | - |
hcfmusp.remissive.sponsorship | CAPES | - |
hcfmusp.remissive.sponsorship | FAPESP | - |
hcfmusp.lim.ref | 2012 | - |
hcfmusp.citation.scopus | 9 | - |
hcfmusp.scopus.lastupdate | 2024-04-12 | - |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - FM/MCM Artigos e Materiais de Revistas Científicas - FM/MOG Artigos e Materiais de Revistas Científicas - HC/ICHC Artigos e Materiais de Revistas Científicas - LIM/17 Artigos e Materiais de Revistas Científicas - LIM/58 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art_CONDI_The_effects_of_conjugated_estrogen_raloxifene_and_soy_2012.PDF Restricted Access | publishedVersion (English) | 487.83 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.